Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01374074 · ClinicalTrials.gov registry record

Racial Disparity in Barrett's Esophagus

A clinical trial of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
255
Enrollment target
1
Study location

NCT01374074 is a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD) that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 255 participants, below the 513-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01374074, a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
255 participants
Enrollment target
1
Study location

Study Summary

The goal of the proposed research is to investigate the molecular mechanisms of racial disparity in Barrett's esophagus (BE), the premalignant lesion of esophageal adenocarcinoma. Specifically, the investigators hypothesize that environmental factors, genetic factors, and potentially gene environment interactions play crucial roles in the observed racial disparity in developing Barrett's esophagus. Patients are recruited through UNC hospitals prior to scheduled esophagogastroduodenoscopy (EGD). Participants complete a questionnaire, have body measurements obtained, and have blood, biopsies, and gastric aspirate collected. Participants also complete a 24 hour pH impedance test.

Study Locations (1)

North Carolina

  • University of North Carolina Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2011-03
Est. Completion 2014-01

What the Registry Record Tells You About NCT01374074

The ClinicalTrials.gov registry entry for NCT01374074 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 513-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (50% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Barrett's Esophagus appearing as the primary indexed condition, and to 0 interventions.

NCT01374074 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01374074 about?

NCT01374074 is a clinical study titled "Racial Disparity in Barrett's Esophagus". The goal of the proposed research is to investigate the molecular mechanisms of racial disparity in Barrett's esophagus (BE), the premalignant lesion of esophageal adenocarcinoma. Specifically, the investigators hypothesize that environmental factors, genetic factors, and potentially gene environmen...

What is the current status of trial NCT01374074?

This trial is currently completed. The enrollment target is 255 participants. The study started on 2011-03. Estimated completion is 2014-01.

What conditions does trial NCT01374074 study?

This clinical trial studies the following conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Intestinal Metaplasia.

Who is sponsoring clinical trial NCT01374074?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01374074 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett's Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.